Fungaemia

Fungemia is the presence of fungi or yeast in the blood. The most common type, also known as candidemia, candedemia, or systemic candidiasis, is caused by ''Candida'' species. Candidemia is also among the most common bloodstream infections of any kind. Infections by other fungi, including ''Saccharomyces'', ''Aspergillus'' (as in aspergillemia, also called invasive aspergillosiis) and ''Cryptococcus'', are also called fungemia. It is most commonly seen in immunosuppressed or immunocompromised patients with severe neutropenia, cancer patients, or in patients with intravenous catheters. It has been suggested that otherwise immunocompetent patients taking infliximab may also be at a higher risk.

Diagnosis is difficult, as routine blood cultures have poor sensitivity.

Signs and symptoms

Symptoms can range from mild to extreme—often described as extreme flu-like symptoms. Many symptoms may be associated with fungemia, including pain, acute confusion, chronic fatigue, and infections. Skin infections can include persistent or non-healing wounds and lesions, sweating, itching, and unusual discharge or drainage.

Risk factors

Pathogens

The most commonly known pathogen is ''Candida albicans'', causing roughly 70% of fungemias, followed by '' Candida glabrata'' with 10%, ''Aspergillus'' with 1% and ''Saccharomyces'' as the fourth most common. However, the frequency of infection by ''C. glabrata'', '' Saccharomyces boulardii'', ''Candida tropicalis'', '' C. krusei'' and '' C. parapsilosis'' is increasing, perhaps because significant use of fluconazole is common or due to increase in antibiotic use.

''Candida auris'' is an emerging multidrug-resistant (MDR) yeast that can cause invasive infections and is associated with high mortality. It was first described in 2009 after being isolated from external ear discharge of a patient in Japan. Since the 2009 report, ''C. auris'' infections, specifically fungemia, have been reported from South Korea, India, South Africa, and Kuwait. Although published reports are not available, C. auris has also been identified in Colombia, Venezuela, Pakistan, and the United Kingdom.

In a single reported instance, ''Psilocybe cubensis'' was reported to have been cultured from a case of fungemia in which an individual self-injected an underprocessed decoction of fungal matter. The patient, who had been experiencing depression, attempted to self-medicate with the mushrooms but was frustrated by the lag time between eating the mushrooms and experiencing the psychedelic effects. In an attempt to bypass this, the patient boiled and filtered the mushrooms into a 'mushroom tea' which was then administered by injection. The patient had multiple organ failure, but this was successfully reversed and the infection treated with antifungal drugs. Two other examples of fungemia as a result of injecting fungal matter in this way have been described in medical literature, both dating to 1985.

Diagnosis

The gold standard for the diagnosis of invasive candidiasis and candidemia is a positive culture. Blood cultures should be obtained in all patients with suspected candidemia.

Treatment

Neutropenic vs non-neutropenic candidemia is treated differently.

An intravenous echinocandin such as anidulafungin, caspofungin or micafungin is recommended as first-line therapy for fungemia, specifically candidemia. Oral or intravenous fluconazole is an acceptable alternative. The lipid formulation amphotericin B is a reasonable alternative if there is limited antifungal availability, antifungal resistance, or antifungal intolerance.

See also

* Bacteremia
* Candidiasis
* Fungicide
* Mycosis

References

External links

{{Mycoses

Animal fungal diseases
Abnormal clinical and laboratory findings for blood
Sepsis